TNF-α and its inhibitors in cancer

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 185-198

  Zidi, Inès ^a   Mestiri, Souhir ^a   Bartegi, Aghleb ^a   Amor, Nidhal Ben ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Anti TNF ; Cancer; Inhibitors; Therapy; TNF

Indexed keywords

ADALIMUMAB; CC 3052; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; IMID; IMMUNOMODULATING AGENT; INFLIXIMAB; LENALIDOMIDE; PHOSPHODIESTERASE INHIBITOR; POMALIDOMIDE; SELCID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RHEUMATIC DISEASE; TUMOR PROMOTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956898009     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9190-3     Document Type: Article

References (147)

1. Carswell E, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666-70. doi:10.1073/pnas.72.9.3666.
2. Feldmann M, et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp. 2004;256:53-69. doi:10.1002/0470856734.ch5.
3. Locksley R, Killeen N, Lenardo M. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104: 487-501. doi:10.1016/S0092- 8674(01)00237-9. (Pubitemid 32201945)
4. Black RA, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-33. doi:10.1038/385729a0. (Pubitemid 27098094)
5. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392-9. doi:10.1016/S0962-8924(00)89088-1.
6. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-25. doi:10. 1056/NEJM199606273342607. (Pubitemid 26193625)
7. Aggarwal B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-56. doi: 10.1038/nri1184.
8. Tartaglia L, Goeddel D. Two TNF receptors. Immunol Today. 1992;13:151-3. doi:10.1016/0167-5699(92)90116-O.
9. Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell. 2004;116:491-7. doi:10.1016/S0092-8674(04)00166-7. (Pubitemid 38264427)
10. Wertz IE, Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev. 2008;19:313-24. doi: 10.1016/j.cytogfr.2008.04.014.
11. Chen G, Goeddel D. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634-5. doi:10.1126/science.1071924. (Pubitemid 34579145)
12. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7:758-65. doi:10.1038/ncb0805-758. (Pubitemid 41079044)
13. Basak S, Hoffmann A. Crosstalk via the NF-kappa B signaling system. Cytokine Growth Factor Rev. 2008;19:187-97. doi: 10.1016/j.cytogfr.2008.04.005.
14. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of JUN and collagenase genes by tumour necrosis factor-alpha. Nature. 1989;337:661-3. doi:10.1038/337 661a0.
15. Muppidi JR, Tschopp J, Siegl RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461-5. doi:10.1016/ j.immuni.2004.10.001.
16. Kruyt FAE. TRAIL and cancer therapy. Cancer Lett. 2008;263:14-25. doi:10.1016/j.canlet.2008.02.003.
17. Anderson G, Nakada MT, DeWitte M. Tumor necrosis factoralpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314-20. doi:10.1016/j.coph.2004.04.004. (Pubitemid 38987055)
18. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14:185-91. doi:10.1016/S1359-6101(03)00022-4. (Pubitemid 36693140)
19. Kruglov A, et al. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev. 2008;19:231-44. doi:10.1016/j.cytogfr.2008.04.010.
20. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50:184-95. doi:10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H. (Pubitemid 30610095)
21. Stübgen J-P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281-92. doi:10.1002/mus.20924. (Pubitemid 351304787)
22. Cope AP, et al. Chronic tumor necrosis factor alter T cells responses by attenuating T cell receptor signalling. J Exp Med. 1997;185:1573-84. doi:10.1084/jem.185.9.1573. (Pubitemid 27203254)
23. Kodama S, Davis M, Faustman D. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci. 2005;62:1850-62. doi: 10.1007/s00018-005-5022-6. (Pubitemid 41188524)
24. Ban L, et al. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci USA. 2008;105:13644-9. doi:10.1073/pnas.0803429105.
25. Manusama E, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996;83:551-5. doi: 10.1002/bjs.1800830438. (Pubitemid 26120788)
26. Eggermont A, de Wilt J, ten Hagen T. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429-37. doi:10.1016/S1470-2045 (03)01141-0.
27. Curnis F, Sacchi A, Corti A. Improving the response of tumors to chemotherapy in mice by targeted delivery of picogram doses of tumor necrosis factor-alpha to tumor vessels. J Clin Invest.2002;110:475-82.
28. Folli S, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993;53:829-36. doi:10. 1002/ijc.2910530521.
29. van Horssen R, Ten Hagen T, Eggermont A. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397-408. doi:10.1634/theo ncologist.11-4-397.
30. ten Hagen T, Seynhaeve A, Eggermont A. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev. 2008;222:299-315. doi:10. 1111/j.1600-065X.2008.00619.x.
31. Fraker DL, Alexander H, Andrich M, Rosenberg S. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor doseescalation study. J Clin Oncol. 1996;14:479-89.
32. Van Horssen R, Ten Hagen TLM, Eggermont AMM. TNF-alpha in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. The Oncologist. 2006;11:397-408. doi:10.1634/ theoncologist.11-4-397.
33. Lejeune F, Rüegg C. Recombinant human tumor necrosis factor:an efficient agent for cancer treatment. Bull Cancer. 2006;93: E90-100.
34. Fajardo L, Kwan H, Kowalski J, Prionas S, Allison A. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol.1992;140:539-44.
35. Alexander HJ, et al. Isolated hepatic perfusion with tumornecrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479-89.
36. Borsi L, et al. Selective targeted delivery of TNF alpha to tumor blood vessels. Blood. 2003;102:4384-92. doi:10.1182/blood- 2003-04-1039.
37. Corti A, Ponzoni M. Tumor vascular targeting with tumornecrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci. 2004;1028:104-12. doi:10.1196/annals.1322.011. (Pubitemid 40361814)
38. Senzer N, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22:592-601. doi:10.1200/JCO.2004.01.227. (Pubitemid 41095061)
39. Chang K, et al. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2008;5:107-11. doi:10.1038/ncpgasthep1033. (Pubitemid 351234280)
40. Mundt AJ, et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004;10:5747-53. doi:10.1158/1078-0432.CCR-04-0296. (Pubitemid 39180951)
41. Chung T, et al. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998;5:344-9.
42. Staba M, Mauceru H, Kufe D, Hallahan D, Weichselbaum R. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998;5:293-300. doi:10.1038/sj.gt. 3300594.
43. McLoughlin JM, et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor a, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol. 2005;12:825-30. doi:10.1245/ASO.2005.03.023. (Pubitemid 41355935)
44. Asher AL, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol. 1991;146:3227-34.
45. Han SK, Brody SL, Crystal RG. Suppression of in vivotumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am J Respir Cell Mol Biol. 1994;11:270-8.
46. Mizuguchi H, et al. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res. 1998;58:5727-30.
47. Larmonier N, et al. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res. 2007;313:2345-55. doi:10.1016/ j.yexcr.2007.03.027.
48. Tselepsis C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071-81. doi:10.1038/sj.onc.1205731.
49. Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor alpha in women with endometriomas and benign and malignant cycstic ovarian tumours. Hum Reprod. 2003;18:1681-5. doi: 10.1093/humrep/deg321. (Pubitemid 36958050)
50. Szlosarek PW, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006;42:745-50. doi:10.1016/j.ejca.2006.01.012.
51. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135-41. doi:10.1016/ S1359-6101(01)00020-X.
52. Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. In: Chernajovsky Y, Nissim A, editors. Therapeutic antibodies. Handbook of experimental pharmacology. 2008, p. 101-129.
53. Huerta-Yepez SM, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fasinduced apoptosis. Clin Immunol. 2006;120:297-309. doi: 10.1016/j.clim.2006.03.015. (Pubitemid 44175895)
54. Mocellin S, Riccardo Rossi C, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35-53. doi:10.1016/j.cytogfr.2004.11.001. (Pubitemid 40279116)
55. Hagemann T, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543-9. doi:10.1093/carcin/ bgh146. (Pubitemid 39162720)
56. Lee HY, et al. A small compound that inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-9 upregulation. Biochem Biophys Res Commun. 2005;336:716-22. doi: 10.1016/j.bbrc.2005.08.154. (Pubitemid 41267284)
57. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat Rev Cancer. 2006;6:227-39. doi:10.1038/nrc1821. (Pubitemid 43292566)
58. Nagai S, et al. Glil contributs to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci. 2008;99:1377-84. doi:10.1111/j.1349-7006.2008.00822.x. (Pubitemid 351761727)
59. Leber TM, Balkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998;78:724-32.
60. Szlosarek PW, Balkwill FR. Tumour necrosis factor: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565-73. doi:10.1016/S1470- 2045(03)01196-3. (Pubitemid 38351714)
61. Zidi I, et al. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci. 2006;63:2669-81. doi:10.1007/s00018- 006-6341-y.
62. Jang W, et al. The -238 tumor necrosis factor-alpha promoterpolymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41-6. doi:10.1016/S0304-3835 (01)00438-4.
63. Hajeer A, et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol. 2000;142:441-5. doi:10.1046/j.1365-2133.2000.03353.x. (Pubitemid 30159064)
64. Marsh H, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer. 2003;89:1096-101. doi:10.1038/ sj.bjc.6601165.
65. Scallon BJ, Arevalo Moore M, Trinh H, Knight DM, Ghrayeb J.Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-9. doi:10.1006/cyto.1995.0029.
66. Mitoma H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factoralpha expressing cells comparison among Infliximab, Etanercept,and Adalimumab. Arthritis Rheum. 2008;58:1248-57. doi:10.1002/art.23447. (Pubitemid 351705913)
67. Daniel PT, Pezzuto A, Dörken B. Humoral immunotherapy and the use of monoclonal antibodies. In: Degos L, LDC, Löwenberg B, editors. Textbook of malignant haematology. Martin Dunitz; 1999, p. 425-46.
68. Tracey D, Klareskog L, Sasso EH, Salfled Jg, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-79. doi:10.1016/ j.pharmthera.2007.10.001.
69. Duclos M, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol. 2006;33:2433-8.
70. Schrumpf Heiberg M, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234-40. doi:10.1002/art.23333. (Pubitemid 351272960)
71. Alonso-Ruiz A, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi: 10.1186/1471-2474-9-52. (Pubitemid 351678129)
72. Carmona L, Gomez-Reino JJS, Group B. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER.Arthritis Res Ther. 2006;8:R72. doi:10.1186/ar1941.
73. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with Etanercept and Infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174. doi:10.1186/ar2084.
74. Farrell R, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-7. doi:10.1111/j.1572-0241.2000.03366.x.
75. St Clair E, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43. doi:10.1002/art.20568. (Pubitemid 39488667)
76. Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681-90. doi:10.1002/art.1780361206. (Pubitemid 23360007)
77. Wagner C, et al. lnfliximab treatment benefits correlate with pbarmacodynamic parameters in Crohn's disease patients. Digestion. 1998;59:124-5.
78. Nakada M, et al. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun.1998;5:491-503. doi:10.3109/ 15419069809005606.
79. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-33.
80. Hommes D, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis. 1997;27:269-77
81. Van Dullemen H, et al. Reduction of circulating secretory phospholipase A, levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A, in healthy humans and active Crohn's disease. Scand J Gastroenterol. 1998;33:1094-8. doi:10.1080/003655298 750026813.
82. Flamant M, Bourreille A. Biothe'rapies et MICI: anti-TNF et nouvelles cibles the'rapeutiques Biologic therapies in inflammatory bowel disease. Rev Med Interne. 2007;28:852-61. doi: 10.1016/j.revmed.2007.06.008. (Pubitemid 350122795)
83. Baert F, et al. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. N Engl J Med. 2003;348:601-8. doi:10.1056/NEJMoa020888. (Pubitemid 36204954)
84. Weinblatt M, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45. doi: 10.1002/art.10697. (Pubitemid 36091645)
85. Van der Heijde D, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double blind, placebocontrolled trial. Arthritis Rheum. 2006;54:2136-46. doi:10.1002/art. 21913. (Pubitemid 44051069)
86. Mease P, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-89. doi:10.1002/art. 21306. (Pubitemid 41447111)
87. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:349-64. doi: 10.1016/j.rdc.2004.02.004. (Pubitemid 38692566)
88. Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the Macaque immune system. Am J Reprod Immunol. 2007;58:138-49. doi:10.1111/j.1600- 0897.2007.00499.x.
89. Kay J, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964-75. doi:10.1002/art.23383. (Pubitemid 351563997)
90. Zhou H, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383-96. doi:10.1177/0091270006298188. (Pubitemid 46294717)
91. Inman RD, et al. Efficacy and safety of Golimumab in patients with ankylosing spondylitis results of a randomized, doubleblind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402-12. doi:10.1002/art.23969.
92. Hutas G. Golimumab, a fully human monoclonal antibody against TNF-alpha. Curr Opin Mol Ther. 2008;10:393-406.
93. Sandborn WJ, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-38. doi:10. 1056/NEJMoa067594.
94. Schreiber S, et al. Maintenance therapy with Certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-50. doi: 10.1056/NEJMoa062897. (Pubitemid 47080388)
95. Winter G, Harris W. Humanized antibodies. Immunol Today. 1993;14:243-6. doi:10.1016/0167-5699(93)90039-N. (Pubitemid 23186983)
96. Stack WA, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor in Crohn's disease. Lancet. 1997;349:521-4. doi:10.1016/S0140- 6736(97)80083-9. (Pubitemid 27092789)
97. Sandborn WJ, et al. An open-label study of the human anti-TNF monoclonal antibody Adalimumab in subjects with prior loss of response or intolerance to Infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-9. doi:10.1111/j.1572-0241.2004.40462.x. (Pubitemid 39421244)
98. Feagan BG, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:617-28. doi:10.1111/j.1365- 2036.2006.02791.x.
99. Sandborn W, et al. Etanercept for active Crohn's disease: a randomized, double blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-94. doi:10.1053/gast.2001.28674.
100. Nanda S, Bathon J. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004;5:1175-86. doi:10.1517/14656566.5.5. 1175. (Pubitemid 38702345)
101. Speirs A. Thalidomide and congenital abnormalities. Lancet. 1962;1:303-5. doi:10.1016/S0140-6736(62)91248-5.
102. Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anticancer agent. J Cell Mol Med. 2002;6:160-74. doi:10.1111/j. 1582-4934.2002.tb00184.x.
103. Combe B. Le thalidomide: vers de nouvelles indications ? Rev Rhum. 2001;68:951-7. doi:10.1016/S1169-8330(01)00208-3. (Pubitemid 33626553)
104. Moreira AL, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-80. doi:10.1084/jem.177.6.1675.
105. Niwayama S, Turk BE, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem. 1996;39:3044-5. doi: 10.1021/jm960284r. (Pubitemid 26260308)
106. Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of Thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-6.
107. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomideis an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-5. doi:10.1073/pnas.91.9. 4082.
108. Keifer JA, Guttridge DC, Ashburner BP, Baldwin ASJ. Inhibition of NF-kappa B activity by thalidomide through suppression of Ikappa B kinase activity. J Biol Chem. 2001;276:22382-7.doi:10.1074/jbc.M100938200.
109. Teo Steven K. Properties of Thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005;7:E14-9. doi: 10.1208/aapsj070103. (Pubitemid 41554303)
110. Haslett P, Corral L, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8? subset. J Exp Med. 1998;187:1885-92. doi: 10.1084/jem.187.11.1885. (Pubitemid 28262451)
111. Laber DA, et al. A phase I study of Thalidomide, Capecitabine and Temozolomide in advanced cancer. Cancer Biol Ther. 2007;6:840-5.
112. Joshua DE. Multiple myeloma: the present and the future. Med J Aust. 2005;183:344.
113. Alessandri C, et al. Autoantibody production in anti-TNF-alphatreated patients. Ann NY Acad Sci. 2007;1110:319-29. doi: 10.1196/annals.1423.034. (Pubitemid 350043021)
114. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601-11. doi:10.1016/S1473-3099(08) 70227-5.
115. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183:205-8.
116. Ozorio G, et al. Autoimmune hepatitis following Infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524-6.
117. Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioglu E. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis. 2008;10:953-4.
118. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133-40. doi:10.1161/01.CIR.0000077913.60364.D2. (Pubitemid 36793081)
119. Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis. 2003;62:ii34-6. doi:10.1136/ard.62. suppl-2.ii34.
120. Askling J, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64: 1414-20. doi:10.1136/ard.2004.033241. (Pubitemid 41623850)
121. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. doi: 10.1001/jama.295.19.2275. (Pubitemid 43736578)
122. Okada S, Siegel J. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA. 2006;296:2201-2. doi:10.1001/jama.296.18.2201-b.
123. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with Infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-7. doi:10.1097/MPG.0b013e 31802f6424.
124. Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma. 2007;48: 1410-3. doi:10.1080/10428190701345433. (Pubitemid 47079370)
125. Drini M, Prichard PJ, Brown GJ, Macrae FA. Hepatosplenic Tcell lymphoma following Infliximab therapy for Crohn's disease. Med J Aust. 2008;189:464-5.
126. Geborek P, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699-703. doi:10.1136/ard.2004.030528. (Pubitemid 40559295)
127. Nair B, Raval G, Mehta P. TNF-alpha inhibitor Etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007;82:1022-4. doi:10.1002/ajh.20926. (Pubitemid 350004395)
128. Bakland G, Nossent H. Acute myelogenous leukaemia following Etanercept therapy. Rheumatology. 2003;42:900-1. doi:10.1093/ rheumatology/keg128.
129. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MMT. Tumor necrosis factor antagonist therapy and lymphoma development twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-8. doi:10.1002/art.10679. (Pubitemid 35453523)
130. Stone JH, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept trial. Arthritis Rheum. 2006;54:1608-18. doi:10.1002/art.21869.
131. HumiraTM (Adalimumab), DN0735V7 CR22-05126. December 20, 2002:16p.
132. Solomon DH. The comparative safety and effectiveness of TNFalpha antagonists. J Manag Care Pharm. 2007;13:S7-18.
133. Curnis F, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185-90. doi:10.1038/81183.
134. Kianmanesh A, et al. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naïve dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther. 2001;12: 2035-49. doi:10.1089/10430340152677395. (Pubitemid 34053489)
135. Manusama ER, et al. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam Preclinical-Clinical Program. Semin Surg Oncol. 1998;14:232-7.doi:10.1002/(SICI)1098-2388(199804/05)14: 3<232::AID-SSU7 >3.0.CO;2-9.
136. Lewis JD. Anti-TNF antibodies for Crohn's disease- In pursuit of the perfect clinical trial. N Engl J Med. 2007;357:296-8. doi: 10.1056/NEJMe078111. (Pubitemid 47080396)
137. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, Omalizumab, Infliximab, Etanercept, Adalimumab, Efalizumab, and Alefacept (Part 2 of 2). J Am Acad Dermatol. 2007;56:e55-79. doi:10.1016/j.jaad.2006.07.019. (Pubitemid 44969298)
138. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor blocking agents Adalimumab, Etanercept, and Infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl II):ii13-6. doi:10.1136/ard.62.suppl-2. ii13.
139. Doan QV, Chiou C-F, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (Adalimumab, Etanercept, and Infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555-69.
140. Chen Y-F, et al. A systematic review of the effectiveness of Adalimumab, Etanercept and Infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
141. Thie'fin G, Morelet A, Heurgue' A, Diebold M-D, Eschard J-P. Infliximab-induced hepatitis: absence of cross-toxicity with Etanercept. Joint Bone Spine. 2008;75:737-9. doi:10.1016/ j.jbspin.2007.12.009.
142. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents: A guide for GPs. Aust Fam Physician. 2007;36:1035-8.
143. Fonseca JE, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors-March 2008 update. Acta Reumatol Port. 2008;33: 77-85.
144. Theis VS, Rhodes JM. Minimizing tuberculosis during antitumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19-30.
145. Gupta A, Street AC, Macrae FA. Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease. MJA. 2008;188:168-70.
146. Tayal V, Kalra B. Cytokines and anti-cytokines as therapeutics-an update. Eur J Pharmacol. 2008;579:1-12. doi:10.1016/j.ejphar.2007.10.049.
147. Schreiber S, et al. A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-18. doi:10.1053/j.gastro.2005. 06.064.